The FDA approved the DNA damage repair inhibitor olaparib, in combination with other therapies, for Castration-resistant or refractory prostate cancer The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza), in combination with...
“It is more important to know what sort of person has a disease than to know what sort of disease a person has.” — Hippocrates The disease: Glioblastoma, the most lethal form of brain...
High cancer death rates in Native Hawaiian and Pacific Islander communities, and thousands of people lose Medicaid for procedural reasons.
Researchers explore mechanisms of chemotherapy-related neurotoxicity at the AACR Annual Meeting 2023.
The FDA granted accelerated approval to the first bispecific T-cell engager to treat two types of B-cell lymphomas The U.S. Food and Drug Administration (FDA) has granted accelerated approval to epcoritamab-bysp (Epkinly) for certain...
Cancer drugs are affected by shortages, and angiogenesis inhibitors make a comeback in combination treatments.
The treatment of cutaneous melanoma has been profoundly transformed by the advent of targeted therapy and immunotherapy, which have prolonged survival in some patients with metastatic disease and reduced the risk of relapse in...
Men are increasingly opting to put off treatment for low-risk prostate cancer, and doctors say it’s a good thing.
Mammography screening recommendation pushed back to age 40, and pancreatic cancer vaccine shows promising immune response.
An increased risk of early death exists even after treatment for childhood cancer, but survivors also have the potential for decades of life after cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More